George Sflomos

Institution: ISREC/EPFL

Address:

SV 2815, Station 19 CH-1015 Lausanne

Email: georgios.sflomos@epfl.ch

Group website: brisken-lab.epfl.ch/team

Phone: 021 693 0784

Research interests:

Experimental Cancer Research and Translational Breast Cancer Studies with an emphasis in ILC

Selected publications:

1.Patient-derived xenograft (PDX) models in basic and translational breast cancer research (Cancer Metastasis Rev 35 (4), 547-573. 12 2016) 2. A Robust Preclinical Model for ERα Positive Breast Cancer Points to the Mammary Epithelial Microenvironment as a Critical Determinant of Luminal Phenotype and Hormone Response, Sflomos G. et al., 2016 (Cancer Cell, 2016 doi: 10.1016/j.ccell.2016.02.002). 3. An Ex Vivo Model to Study Hormone Action in the Human Breast. Sflomos G., et al., J. Vis. Exp. 2015. 4. A new Achilles’ heel in breast cancer? Sflomos G. and Brisken C., Oncotarget, 2013. 5. Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast. Tanos T., Sflomos G., et al., Science Translational Medicine, 2013. 6. SARA and RNF11 Interact with Each Other and ESCRT-0 Core Proteins to Regulate Degradative EGFR Trafficking. Kostaras E., Sflomos G., Pedersen NM., Stenmark H., Fotsis T., Murphy C., Oncogene 2013, doi: 10.1038/onc. 7. ERBIN is a Novel SARA-Interacting Protein: Competition between SARA and SMAD2/3 for Binding to ERBIN. Sflomos G., Kostaras E., Panopoulou E., Pappas N., Kyrkou A., Politou AS., Fotsis T., Murphy C., J. Cell Sci., 2011, doi: 10.1242/jcs.062307). 8. The histone chaperone SET/TAF-Ibeta interacts functionally with the CREB-binding protein. Karetsou Z., Martic G., Sflomos G., Papamarcaki T., Biochem. Biophys. Res. Commun., 2005, PMID:16061203).

Members List